proliferative index were mostly positive, while tumours characterized by a higher growth fraction had low p27 KIP1 protein levels (Sánchez-Beato et al, 1997) , although in an earlier study performed by this group some exceptions to this rule were found in the group of aggressive B-cell lymphomas, including Burkitt's lymphoma and diffuse large B-cell lymphoma (DLBCL). Only very rare genetic alterations have been found in the p27 KIP1 gene (Shiohara et al, 1994; Kawamata et al, 1995; Morosetti et al, 1995; Pietenpol et al, 1995; Watanabe et al, 1995) , suggesting that if inactivation of this CDKi takes place in human tumours, it would be through a mechanism other than genetic mutation, unlike the INK4 family.
Initial studies performed on breast, lung and colorectal cancer and melanoma, coincide in indicating that a high level of p27 KIP1 expression is associated in these tumours with a lower degree of malignancy (Fredersdorff et al, 1997) or a better clinical outcome (Bani et al, 1997; Catzavelos et al, 1997; Esposito et al, 1997; Loda et al, 1997; Porter et al, 1997) , in spite of the fact that in these tumours there is no clear relationship between p27 KIP1 expression and growth fraction. Further studies offer differing data showing that a high level of p27 KIP1 expression may be associated with a more aggressive course in breast cancer and B-cell lymphocytic leukaemia (B-CLL) (Sgambato et al, 1997; Vrhorac et al, 1998) . The presence of an elevated level of p27 KIP1 protein expression in subsets of tumours with high proliferative indexes suggests that the abnormally expressed protein lacks the functional capacity to inhibit cell cycle progression (Fredersdorf et al, 1997; Sgambato et al, 1997; Quintanilla-Martinez et al, 1998; Yatabe et al, 1998) .
DLBCLs form a heterogeneous group in terms of clinical presentation, histology, immunophenotype, genetic alterations, response to treatment and prognosis (Harris et al, 1994) . Recent findings suggest that the overall outcome for patients with DLBCL is decided by a combination of different clinical and biological variables, the expression of some of these cell cycle regulator proteins being specifically associated with different clinical features of tumours. Overall analysis showed that an extended overall survival (OS) time is associated with low growth fraction, low expression of p53 and MDM2 proteins and high Rb expression. In contrast with this finding, higher disease-free survival (DFS) time is mainly associated with low bcl2 expression (Slymen et al, 1990; Yamanaka et al, 1992; Miller et al, 1994; Piris et al, 1994; Martin et al, 1995; Hermine et al, 1996; Hill et al, 1996; Kramer et al, 1996; Gascoyne et al, 1997; Grogan et al, 1988; Sánchez et al, 1998) Earlier studies in non-Hodgkins lymphomas (NHLs) pointed to the presence of a small group of DLBCL characterized by an unusually high level of p27 KIP1 expression (Sánchez-Beato et al, 1997; Quintanilla-Martinez et al, 1998) , in which the opposing relationship between p27 KIP1 and MIB1 expression seemed to be lost. The main purpose of this work was to analyse the expression of this protein in greater depth, and to determine the clinical relevance of p27 KIP1 expression in this lymphoma type. To this end the clinical characteristics of a series of 133 cases of DLBCL were analysed, while simultaneously studying the relative clinical relevance of MIB1 expression, which is a growth fraction marker.
MATERIALS AND METHODS

Tissue samples, patients and clinical variables
Tumour specimens from 133 DLBCLs were obtained from the routine files of the Virgen de la Salud Hospital, and diagnosed according to the criteria used in the REAL classification (Harris et al, 1994) . Consecutively diagnosed patients from 1980 to 1995 were included in the study if their cases fulfilled the following conditions:
• The initial diagnosis of DLBCL had to be made on a representative biopsy obtained before treatment.
• Paraffin-embedded, formalin-fixed tissue blocks from the diagnostic biopsy had to be available for immunohistochemical studies.
• All patients had to be treated with the aim of achieving a cure.
Untreated patients were excluded. Treatment decisions were not based on molecular and/or immunohistochemical features. Patients were treated according to standard therapeutic protocols, including polychemotherapy (CHOP or third-generation regimes, depending on IPI and clinical stage) and radiotherapy or surgery for localized tumours. A combination of these treatments was used for certain patients.
Age, clinical stage, performance status, LDH and the number of extranodal sites of the disease were used, as determined by the International Prognostic Index (IPI). IPI was grouped as 0-1, 2, 3 and 4-5. Complete remission (CR) was defined as the absence of clinical and radiological evidence of disease for a minimum of 4 weeks. Other degrees of response were considered to represent treatment failure. Patients who died of causes unrelated to the disease were censored at the time of death. OS was measured as the interval between the beginning of treatment and the death of the patient or the date of the last follow-up revision. Patients known to have died after finishing the treatment due to causes unrelated to the lymphoma (one colorectal cancer diagnosed shortly after the diagnosis of lymphoma, one acute myocardial infarct and one elderly patient with Alzheimer's disease) were considered as censored for the purposes of survival analysis. DFS was estimated for patients having CR, by measuring the interval between the end of the treatment and relapse or death attributable to the tumour, or the date of the last follow-up revision in patients who had no relapse. All data were checked for validity and consistency.
Antibodies
p27
KIP1 protein was detected with a monoclonal antibody (mAb) from Transduction Laboratories, K25020 (1:1000 dilution), generated against the full-length mouse KIP1 protein. This antibody exclusively recognizes a 27 kDa protein, as previously shown by Mantel et al (1996) . Ki-67, a nuclear protein expressed in the G1, S and G2/M phases, was detected by the MIB1 mAb (Novocastra) (1:50 dilution). It was also used as the control of antigenic preservation and successful antigenic retrieval.
Immunostaining techniques
All immunostaining techniques were performed in paraffinembedded tissue. A previous step of heat-induced antigen retrieval technique was used for all four antibodies. This took the form of pressure cooker heating in a solution of 0.01 M sodium citrate prior to incubation with the antibody (Ab). Following incubation with the primary Ab, immunodetection was performed with biotinylated anti-mouse immunoglobulins, followed by peroxidaselabelled streptavidine (LSAB-DAKO) and with diaminobencidine chromogen as substrate. All immunostaining was performed using the Techmate 500 (DAKO) automatic immunostaining device.
Incubation omitting the specific Ab, as well as with unrelated Abs, was used as a control of the technique. Internal control provided by benign reactive T-cells, macrophages, epithelial or endothelial cells was used to evaluate p27 KIP1 and MIB1.
Quantitative studies
All scoring ), using the morphology of the cells as criterion. A cut-off of 5% of tumoural cells was used for p27 KIP1 expression, since this threshold roughly separates tumours with null or isolated p27 KIP1 expression from those characterized by an intermediate or high level of expression, as determined by semi-quantitative analysis. This threshold divides the series into groups of similar size (p27 ≤ 5%: 57.9% cases; p27 > 5%: 42.1% cases), and this and closer cut-off points were found to be statistically highly significant. Moreover, the cut-off points at 4 and 6% were statistically significant, although they had the disadvantage of being less easily reproducible.
The Quantitative Proliferation Index application of the CAS 200 was used for the analysis of MIB1, since this measure of the tumoural growth fraction has been shown to correlate significantly with the clinical outcome in DLBCL (Sanchez-Bezto et al, 1997) . This program determines a value expressing the growth fraction of the tumour, related to the number of proliferating cells. Representative fields down to a minimum of 30 000 µ 2 were selected (approximately five fields with 45× objective and 10× ocular lenses). Sectional analysis was carried out, focusing on tumoural areas. A cut-off point of 20% of positive cells was used, as a previous study showed that this point discriminated between groups presenting different clinical behaviour. Categories were therefore classified as equal to or less than 20%, or greater than 20% (Sánchez et al, 1998) .
Statistical study
The relationship between p27 KIP1 and the proliferative index The distributions of p27 KIP1 and MIB-1 were compared in order to establish any possible associations, using the Spearman correlation coefficient for doubly ordered data, and Kruskal-Wallis test for single ordered data. Differences were considered significant if P < 0.05.
Survival: univariate analysis
The clinical variables analysed for survival studies were those included in the IPI (measured as 0-1, 2, 3, 4-5), which are: age (≤ 60 vs > 60), gender (female vs male), clinical stage (I + II vs III + IV), LDH (normal vs > normal). Actuarial survival curves (OS and DFS) were plotted using the Kaplan and Meier method (Kaplan and Meier, 1958) . The statistical significance of associations between individual variables, OS and DFS was determined by using the log-rank test (Mantel, 1966 hazard univariate analysis was also performed independently for each variable, calculating the relative risk (RR) of each variable in terms of survival and confidence interval (CI) (Cox, 1972) .
Survival: multivariate analysis
In order to identify the factors which might be of independent significance in influencing survival (OS and DFS), a Cox backward proportional hazard model was run (Cox, 1972) . Variables included in the maximum models were: IPI (0-1, 2, 3 or 4-5), MIB1 (≤ 20% or > 20%), p27 KIP1 (≤ 5% or > 5%). The lower values of IPI, MIB1 and p27 KIP1 , which had been found to be associated with longer survival probability, were used as reference levels (RL). All P-values were two-sided, and values of 0.05 or less were considered to indicate statistical significance.
The SPSS software package was used for all statistical analysis.
RESULTS
Characteristics of the patients
The clinical characteristics of the 133 patients included in this analysis have already been published (Sánchez et al, 1998) .
Immunohistochemical study p27 KIP1 nuclear protein expression was observed in tumoural cells with a signal range of from 0.00 to 95.00 and with a median of 3.00. Null p27 KIP1 staining was seen in 21 cases. p27 KIP1 staining was found most frequently in a low to intermediate proportion of the tumoural cells. For survival analysis, a cut-off point of 5% of p27 KIP1 -positive cells was used, which divides the series into two groups, corresponding approximately to cases found by semiquantitative analysis as negative or low-expression versus those with intermediate or high levels of expression (p27 ≤ 5%: 77 cases; p27 > 5%: 56 cases). A smaller group of seven cases (corresponding to percentile 95) showed a very high intensity of staining of most tumoural cells (Figure 1) . A histogram of the overall distribution of p27 KIP1 reactivity is shown in Figure 2 . MIB1 expression was observed in all cases, with a positive percentage of cell staining varying from 2.912 to 55.94 (median: 22.030) (Figure 1 ). In 73 cases (54.9%) the growth fraction was greater than 20%, this threshold having been found to be clinically relevant in previous studies (Sánchez et al, 1998) . No significant correlation was found between p27 KIP1 and MIB-1 expression, 
Survival analysis
Univariate and multivariate survival analyses were performed to analyse the prognostic significance of p27 KIP1 expression. MIB1 expression and the clinical parameters included in the IPI were included as references.
Univariate study
Investigation of OS by Cox's analysis showed that high IPI (P = 0.0004), MIB1 > 20% (P = 0.0199) and p27 KIP1 > 5% (P = 0.0320) were significantly associated with shorter OS. The study of DFS showed that a high expression of p27 KIP1 (P = 0.0412) is significantly associated with shorter DFS. No significant relationship was found for high MIB1 or IPI (Table 1 ). Figure 4A shows the plots for OS, while Figure 4B shows the plot for DFS by Kaplan-Meier analysis and log-rank test.
Multivariate study
Only low p27 KIP1 expression was found to be a parameter associated with prolonged OS (P = 0.0145), together with the clinical variables included within the IPI (P = 0.0010). The significance of MIB1, as found in univariate analysis, was absent from this series. When analysing DFS, only a high p27 KIP1 value was found to be significantly associated with a shorter DFS time (P = 0.0424) ( Table 1) .
DISCUSSION
This study confirms that there is a group of DLBCL characterized by an anomalous p27 KIP1 expression, showing that in the DLBCL group as a whole the inverse relationship found in normal lymphoid tissues between p27 KIP1 and MIB1 expression is lacking. This anomalous p27 KIP1 expression was also associated with an adverse clinical outcome in univariate as well as multivariate analysis.
This finding contradicts observations in reactive lymphoid tissue, where p27 KIP1 expression is always associated with quiescent status, as shown by immunohistochemistry of reactive lymph nodes and tonsils, flow cytometry and Western blot studies of phytohaemaglutinin-stimulated peripheral blood lymphocytes. These show that the p27 KIP1 protein is mainly found in MIB-1 negative quiescent lymphocytes, its expression being down-regulated along cell cycle progression (Sánchez-Beato et al, 1997) . Thus benign centroblasts, the proliferating B-cell subset of the germinal centre and the supposed normal counterpart of most DLBCL, usually show a MIB1+, p27-phenotype, which is lost to a certain extent in DLBCL. This had already been noticed in a previous study of NHL by our group, in which the existence of a small group of cases of Burkitt's lymphoma and DLBCL with this anomalous nuclear p27 KIP1 accumulation was described (Sánchez-Beato et al, 1997) ; these results were confirmed by further studies by Quintanilla-Martínez et al (1998) and Erlanson et al (1998) . A more detailed study was therefore performed. This analysed a larger series of cases using a more sensitive technique and quantified the results with a more analytical procedure, including statistical analysis of the relationship between p27 KIP1 , MIB1 and survival probability. This made it possible to confirm and expand earlier observations, indicating that a gradient of p27 KIP1 expression may be seen in DLBCL. Contrary to what was expected on the basis of the findings in non-tumoural tissues and other tumours, p27
KIP1 expression appears to be associated with an unfavourable clinical course, thereby supporting the hypothesis that this abnormal accumulation of p27 KIP1 protein is deregulated (Sgambato et al, 1997) . To exclude the possibility that the adverse effect of p27 KIP1 expression on survival could be attributed exclusively to the small group of cases with very high p27 KIP1 expression, we repeated the analysis excluding the cases with values of p27 > 25%, the same findings being repeated in this group (data not shown). This same series of patients was the subject of a recent report showing that high growth fraction is an adverse prognostic factor in multivariate analysis (Sánchez et al, 1997) . Now, and once p27 KIP1 is included in the analysis, the predictive value of MIB1 is lost in favour of that of p27 KIP1 . The techniques used here for the quantitative analysis of p27 KIP1 and MIB1 reflect the difficulties arising in estimating these in DLBCL. As is the case for most reactive T-cells, endothelial cells and histiocytes are p27 KIP1 -positive. We therefore decided to count the cells manually, thereby selecting tumoural cells exclusively on the basis of their morphology. This made it possible to recognize and estimate the presence of a minority p27-positive tumoural cell subpopulation in a significant group of DLBCL. This finding was also described in the other analysis published to date of p27 KIP1 expression in DLBCL, thereby underlining the consistency of these techniques and the reproducibility of the results described. Thus, the studies of Quintanilla-Martínez et al (1998) and Erlanson et al (1998) both describe the presence of anomalous p27 KIP1 expression in a subset of DLBCL cases, together with an associated loss of the normal p27/MIB1 ratio found in normal cells.
Nevertheless, software specifically designed for the recognition of the growth fraction of tumours was used for MIB1 analysis, since most positive cells in DLBCL are members of the tumoural cell population, which makes it possible to use an image analysis program. A relatively low percentage of proliferating cells was found in this study, depending of the characteristics of the software used, and this must be taken into consideration when comparing these values with those corresponding to other series.
Although the loss of the inverse relationship between p27
KIP1
and MIB-1 expression has been described previously in different studies of breast and colorectal cancer specimens and derived cell lines (Catzavelos et al, 1997; Fredersdorf et al, 1997; Lodu et al, 1997; Sgambato et al, 1997) , the existence of an adverse clinical significance for increased expression of p27 KIP1 in a specific tumoural type has only been rarely noticed. Indeed, earlier reports emphasized that a more favourable clinical outcome is usually associated with a high level of p27 KIP1 expression, as seen in nonsmall-cell lung cancer (Esposito et al, 1997) , breast cancer (Catzavelos et al, 1997; Porter et al, 1997) , colorectal cancer . A recent report by Erlanson et al (1998) found that, when all histological types of NHL are taken into consideration, high p27 KIP1 values are associated with longer survival probabilities, and therefore probably reflect the fact that the study simultaneously includes different entities, while it does not analyse the specific meaning of p27 KIP1 expression in each histological type. Nevertheless, when considering a specific entity like B-CLL, a recent analysis by Vrhovac et al (1998) illustrates the same phenomenon found here, i.e. high p27 KIP1 levels associated with a poorer overall prognosis, which appeared to be related to the association between high p27 KIP1 and apoptosis resistance. These results overlap those of other reports in epithelial tumours, in which an anomalous deregulated p27 KIP1 expression in some tumoural cell types has been described (Sgambato et al, 1997; Yatube et al, 1998) .
It has been proposed that p27 KIP1 overexpression is involved in the drug resistance displayed by solid tumours, and the suggestion has even been made that tumour-targeted p27 KIP1 antagonists could be used in conjunction with conventional anticancer therapy (Croix et al, 1996) . In B-CLL it has been shown that an increased p27 KIP1 level protects cells against apoptosis, this being reverted after fludarabin exposure (Vrhorac et al, 1998) . These experimental data could explain the shorter survival in the patients analysed here.
This abnormally accumulated p27 KIP1 protein seems to lack the capacity for inhibiting Cyclin E-CDK2 complexes, since these aggressive B-cell lymphomas have a high proliferative index and an unfavourable clinical outcome. This situation has also been observed in human breast cancer cell lines, where an increase in p27 KIP1 expression was paralleled by an increase in the level of Cyclin D1 and Cyclin E. As p27 KIP1 expression is mainly regulated at a post-transcriptional level, it has therefore been suggested that there is a homeostatic mechanism for the up-regulation of p27 KIP1 , induced by overexpression of Cyclin D1 or Cyclin E (Sgambato et al, 1997) . Additional works by Blain et al (1997) , Cheng et al (1998) , Reynisdottir and Massague (1997) and Soos et al (1996) have shown that a high level of p27 KIP1 expression may be found in growing cells, confirming that this negative regulator of the cell cycle is kept inactive by adhesion to Cyclin D-CDK4 complexes. This could also be an hypothetical explanation for the anomalous p27 KIP1 expression in this group of DLBCL. It is still not known if the adverse clinical meaning of p27 KIP1 expression in DLBCL is the direct consequence of the accumulation of this protein, or whether it is merely a reflection of a deeper alteration of cell cycle regulator genes leading to this anomalous p27 KIP1 expression.
